BIOFLOW-III

BIOFLOW-III

Clinical Study

Investigating Orsiro drug-eluting coronary stent

Conclusion

  • In this all-comers setting a low TLF rate of 5.1 % was observed within the first 12 months, which demonstrates safety and effectiveness of the Orsiro Hybrid Stent.
  • The results observed in this “real world” population demonstrate a low TLF rate comparable to other state of the art DES at 12 months.
  • In comparison with other published trials in patients with STEMI, Orsiro shows a low TLF rate.

Patient and lesion characteristics

Image
Patient and lesion characteristics
Image
Patient and lesion characteristics

Study Design

International, prospective, multi-center open-label, registry of the Orsiro drug-eluting stent in daily clinical practice.

  • Coordinating clinical investigator: Prof. Dr. Johannes Waltenberger, Universitätsklinikum Münster, Germany
  • Pre-defined sugroups: Diabetic patients, Small vessels (≤2.75 mm), Chronic Total Occlusion, Acute MI (STEMI and NSTEMI)
  • Post-hoc subgroups: B2/C lesions, Multivessel disease (MVD), STEMI vs NSTEMI
Image
study design image

Primary endpoint results

Image
Primary endpoint graph

Downloads


Image
Orsiro Image

Vascular Intervention

Drug-Eluting Stent

Image
Orsiro Image

Vascular Intervention

Clinical Study


Disclaimer
© BIOTRONIK AG
All rights reserved. Specifications are subject to modification, revision and improvement.